The National Cancer Institute intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications for pilot/exploratory research on the confluence of cancer stigma and HIV stigma in HIV-positive individuals diagnosed with cancer. This NOFO will utilize the R21 grant mechanism (clinical trial optional), which is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development. Up to three (3) R21 awards are expected to be funded as part of the initiative. Research projects will advance the current understanding of the confluence of cancer stigma and HIV stigma in people with HIV (PWH) diagnosed with cancer; investigate the resultant impact of these dual stigmas on cancer outcomes among PWH with cancer; and promote research in diverse domestic and international contexts, focusing on regions in which the HIV-cancer burden is elevated. Pilot interventional research, which addresses modifiable mechanisms of stigma that contribute to negative cancer outcomes among PWH with cancer, is also suitable for this funding mechanism. The NOFO is expected to be published in late Summer 2024 with an expected application due date in late Fall 2024. Details of a pre-application webinar will be announced after the publication of the NOFO. This Notice is being provided to allow sufficient time for potential applicants with relevant expertise and insights to consider applying for this NOFO. Potential applicants are encouraged to view the presentation of this initiative to the Joint Virtual Meeting of the NCI Board of Scientific Advisors and the National Cancer Advisory Board available at https://videocast.nih.gov/watch=54859 beginning at 3 hour, 39 minutes. Presentation slides are downloadable at: https://deainfo.nci.nih.gov/advisory/joint/0624/Vanderpool.pdf.
